Zealand announces ne
Zealand announces new timelines for a U.S. FDA decision on iGlarLixi, the fixed-ratio combination of lixisenatide (AdlyxinTM) and Lantus®, for the treatment of type 2 diabetes
August 19, 2016 18:23 ET | Zealand Pharma A/S
The FDA had requested updated information on the pen delivery device for iGlarLixi as part of its New Drug Application, which has been submitted by Sanofi    Consequently, the...
Zealand meddeler ny
Zealand meddeler ny tidsfrist for en FDA-afgørelse vedrørende iGlarLixi, præmiks-kombinationen af lixisenatid (Adlyxin™/Lyxumia®) og Lantus®, til type 2-diabetes
August 19, 2016 18:23 ET | Zealand Pharma A/S
Som en del af registreringsansøgningen for iGlarLixi har FDA anmodet Sanofi om opdateret information på injektionspennen, hvilket er indsendt I forlængelse heraf har FDA forlænget deres...
Notice of Zealand’s
Notice of Zealand’s interim report for H1 2016 and related conference call
August 17, 2016 07:17 ET | Zealand Pharma A/S
On the day of release, Thursday 25 August 2016 at 2.00pm CET, Zealand’s senior management will host a conference call. The conference call can be accessed via live audio webcast from Zealand’s...
Dato for offentliggø
Dato for offentliggørelse af Zealands delårsrapport for 1. halvår 2016 samt tilhørende telefonkonference
August 17, 2016 07:17 ET | Zealand Pharma A/S
På dagen for offentliggørelse, torsdag 25. august 2016 kl. 14.00 afholder Zealands ledelse en telefonkonference. Telefonkonferencen kan tilgås via webbaseret lydspor fra Zealands hjemmeside....
Phase II results wit
Phase II results with dasiglucagon (ZP4207) support its potential for use in a ready-to-use rescue pen to treat severe hypoglycemia in diabetes
August 11, 2016 14:28 ET | Zealand Pharma A/S
  In the Phase II trial, all type 1 diabetes patients treated with dasiglucagon had a clinically relevant increase in blood glucose levels after an insulin-induced hypoglycemic event...
Fase II-resultater u
Fase II-resultater understøtter dasiglukagons (ZP4207) potentiale som en pen ”klar-til-brug” til nødbehandling af akut, svær hypoglykæmi i diabetes
August 11, 2016 14:28 ET | Zealand Pharma A/S
  I fase II-studiet opnåede alle type 1-diabetikere, som blev behandlet med dasiglukagon, en klinisk relevant stigning i deres blodsukkerniveau efter et tilfælde af insulin-induceret...
Licensindtægtsrappor
Licensindtægtsrapport for 2. kvt. 2016 og opdatering på lixisenatid (Lyxumia®/AdlyxinTM) og iGlarLixi
July 29, 2016 01:36 ET | Zealand Pharma A/S
Licensindtægter på 6,4 mio. kr. fra Sanofis salg af Lyxumia® (lixisenatid uden for USA) i 2. kvt. 2016 FDA i USA godkendte fornylig lixisenatid under navnet AdlyxinTM til behandling af type...
Royalty report for Q
Royalty report for Q2 2016 and update on lixisenatide (Lyxumia®/AdlyxinTM) and iGlarLixi
July 29, 2016 01:36 ET | Zealand Pharma A/S
Royalty revenue of DKK 6.4 million / €0.9 million in Q2 2016 on Sanofi’s sales of Lyxumia® (lixisenatide outside the U.S.) Recently, the U.S. FDA approved lixisenatide as AdlyxinTM to treat...
FDA godkender lixise
FDA godkender lixisenatid under navnet AdlyxinTM til behandling af voksne med type 2-diabetes i USA
July 28, 2016 00:08 ET | Zealand Pharma A/S
Godkendelsen baner vej for, at Sanofi kan lancere det første lægemiddel, opfundet af Zealand, i USA   Udløser en milepælsbetaling på 34 mio. kr. fra Sanofi   FDA...
FDA approves lixisen
FDA approves lixisenatide as AdlyxinTM for the treatment of adults with type 2 diabetes in the U.S.
July 28, 2016 00:08 ET | Zealand Pharma A/S
Approval paves the way for launch by Sanofi of the first Zealand invented product in the U.S.   Triggers a $5 million milestone payment from Sanofi   FDA is currently...